- Company
- MA experts admit headquarters’ “Korea Passing” orders
- by Kim, Jin-Gu Nov 28, 2019 06:14am
- With one phenomenon, there are two interpretations. The government and pharmaceutical industry are showing polarizing views on the current situation and the cause of Korea Passing phenomenon. As if they are speaking in different languages, their prospective and proposed solutions are like parallel lines never crossing each other’s path.
- Company
- Inflximab injection ‘Remsima SC’ good to go in EU
- by Lee, Seok-Jun Nov 27, 2019 11:06pm
- On Nov. 26, Celltrion announced its hypodermic injection Remsima SC got the green light from European authority. The injection was approved on indication of rheumatoid arthritis in 120 mg dose. Remsima SC is the first subcutaneous formulation of inflximab to have passed by the European regulator. Remsima SC would be available in 31 Europ
- Company
- Handok has domestic copyright of Exelon & Trileptal
- by An, Kyung-Jin Nov 27, 2019 06:42am
- Novartis Korea handed over copyrights of two neurology products including dementia medicine 'Exelon' to Handok pharmaceuticals. The intention is to organize copyrights for four medicines that were in charge of the department of neurology and concentrate sales marketing activities on the company's flagship products, including new products.
- Company
- Saxenda easily leads obesity market with KRW 32 bln by 3Q
- by Chon, Seung-Hyun Nov 27, 2019 06:41am
- Novo Nordisk’s Saxenda reaffirmed its unmatched leadership in obesity treatment market. Up to the third quarter this year, the treatment’s accumulated sales surpassed 30 billion won. And also Saxenda’s market share is stabilizing at over 30 percent. According to a pharmaceutical industry research firm IQVIA on Nov. 26, the overall obesity
- Company
- Talking points on ‘Korea Passing’ in pharma industry
- by Eo, Yun-Ho Nov 27, 2019 06:36am
- The well-known expression ‘Korea Passing’, recently used to describe a phenomenon related to foreign affair discrepancies, does not mean the same in pharmaceutical industry. When it comes down to the Korean pharmaceutical industry, the expression does not indicate the U.S. and North Korea neglecting South Korea during the Korean peni
- Company
- The third JAK1 inhibitor,↑competition in Korea
- by Eo, Yun-Ho Nov 24, 2019 09:58pm
- It is the third rheumatoid arthritis drugs that is expectecd to enter domestic market. According to the industry, Abbie recently filed an application for permission to use 'Upadacitinib' for JAK inhibitors. Given the approval from the FDA in US on the 16th of last month, it is rapidly knocking on the Korean market. Abbie demonstrated t
- Company
- Big5 hospitals adds Glead’s new HIV option Biktarvy
- by Eo, Yun-Ho Nov 24, 2019 09:58pm
- Glead’s new HIV combination drug, Biktarvy is landing its code on tertiary hospital’s prescription list. According to pharmaceutical industry source, Biktarvy has been passed by drug committee (DC) at the Big Five tertiary hospitals in Korea, including Seoul National University Hospital, Samsung Seoul Medical Center, Severance Hospita
- Company
- FDA Initiates biologics license of SB8, Samsung Bioepis
- by Chon, Seung-Hyun Nov 22, 2019 06:32am
- Samsung Bioepis announced on the 20th that FDA has initiated the approval and evaluation of the 'SB8' biosimilar of Avastin. In September, the FDA completed BLA for approval and entered into full-scale review for product approval Avastin, the original drug in Roche, has indications for metastatic colorectal cancer and non-small cell lung
- Company
- Localization of Korean pharmaceuticals in Vietnam is pouring
- by Nho, Byung Chul Nov 22, 2019 06:32am
- Recently, listed pharmaceutical companies are stepping up their efforts to localize Vietnam, which has been spotlighted as a Pharmerging market. Pharmaceutical companies investing in Vietnam include Chong Kun Dang (local branch), JW Pharmaceuticals(acquired Euvipharm), Korea United Pharm. Inc. (local plant), Ctcbio (joint plant),Shin Poong
- Company
- Teva-Handok turns around and readies CNS for next year
- by Eo, Yun-Ho Nov 22, 2019 06:32am
- Teva-Handok is shooting for business expansion as it scores a turnaround. One of the most prominent multinational pharmaceutical companies, Israel-based Teva was the talk of the year 2013 in Korean pharmaceutical industry when it entered into a joint venture with a Korean pharmaceutical company, Handok. But, Teva-Handok’s performan
